Operation Warp Speed officials said they plan to release 6.4 million vaccines against coronavirus disease 2019 (COVID-19) in the initial distribution; OxyContin manufacturer Purdue Pharma pleads guilty to role in opioid epidemic; spotlighting difficulty in employer testing for COVID-19.
Yesterday, officials from the US government’s Operation Warp Speed program said they plan to release 6.4 million coronavirus disease 2019 (COVID-19) vaccine doses across the nation in its initial distribution after the first vaccine is cleared for emergency use. According to Reuters, officials noted that states and other jurisdictions had been informed last Friday of their estimated vaccine allocations in the first shipments, with governors expected to determine how best to distribute the vaccine within their respective states.
As reported by the Associated Press, OxyContin manufacturer Purdue Pharma pleaded guilty yesterday to 3 criminal charges, including providing misleading information to the Drug Enforcement Administration to boost company manufacturing quotas, paying doctors to write more prescriptions for painkillers, and paying an electronic health records company to send doctors information on patients to encourage the prescription of opioids. Conducted in a virtual hearing with a federal judge in Newark, New Jersey, the guilty pleas were entered by Purdue board chairperson Steve Miller. The company’s guilty plea deal includes penalties and forfeitures totaling $8.3 billion, although Purdue is only responsible for a fraction of that cost in a direct payment to the federal government, $225 million.
While the CDC has issued guidance to employers to include testing for COVID-19, an article published by Kaiser Health News detailed the difficulty cited by employers in testing amid the pandemic. The price to regularly test workers, particularly for tests with a shorter result turnaround, such as polymerase chain reaction, can be up to $135 with a 36- to 48-hour turnaround and $250 with a 1-day testing turnaround. Typically, public health departments would work directly with employers to administer testing, but these local agencies are said to be chronically underfunded and overworked.
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria
April 15th 2025Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More